XML 60 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Discontinued Operations - Summary of Income (Loss) from Discontinued Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Apr. 01, 2024
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Total Net Sales     $ 132,785 $ 409,284 $ 450,570
Cost of products sold, excluding intangible asset amortization     (47,947) (113,867) (130,719)
Related party cost of products sold, excluding intangible asset amortization     0 (97) (721)
Intangible asset amortization     0 (52,840) (53,885)
Research and development     (7,562) (26,559) (31,544)
Selling, general and administrative     (75,403) (247,926) (270,812)
Restructuring and other cost reduction initiatives     (1,660) (13,068) (8,795)
Acquisition, integration, divestiture and related     (11,770) (175) (2,850)
Other (expense) income, net     (384) (457) 746
Interest expense, net [1]     (6,259) (16,422) (7,409)
Loss from discontinued operations before income taxes     (18,200) (62,127) (55,419)
Adjustment of spine disposal group to fair value   $ 11,100 11,143 [2] (289,456) [2] 0 [2]
Gain on sale of spine disposal group $ 11,100   11,079 0 0
Benefit for income taxes from discontinued operations     3,983 14,350 38,442
Income (Loss) from discontinued operations, net of tax     8,005 (337,233) (16,977)
Third Party Net [Member]          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Total Net Sales     132,785 409,181 449,806
Related Party Net [Member]          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Total Net Sales     $ 0 $ 103 $ 764
[1] A portion of the interest on our Term Loan (as defined and described in Note 9) was allocated to discontinued operations consistent with the amount of proceeds used to repay a portion of the amounts outstanding under our Term Loan in accordance with our Credit Agreement (as defined and described in Note 9).
[2] We performed an impairment analysis of the spine segment in December 2023 on a held-for-sale basis. The fair value of consideration to be received upon closure of the transaction was less than the carrying value of the spine segment's net assets, resulting in a write-down of $289.5 million. We updated our analysis as of March 31, 2024, immediately prior to the sale, which resulted in a reduction of the December 2023 write-down of $11.1 million.